Key Points Alopecia areata incidence increased globally between 1990 and 2021. Teh condition is linked to mental health issues and reduced quality of life. Regional disparities exist, with higher rates in north America. Comorbidities like atopic dermatitis and anxiety disorders show strong correlations. Global Rise in Alopecia Areata Cases Examined updated June 02, […] … Read more
Alopecia areata cases increased from 1990 to 2021, highlighting the need for further research into socioeconomic factors and disease burden. | Image Credit: Yurii Kibalnik – stock.adobe.com Global incidence of alopecia areata increased from 1990 to 2021 with age-standardized incidence rates (ASIR) slightly declining, highlighting the complex socioeconomic factors, health care access, and disease burden … Read more
A specific type of patch test for hair care products and allergenic reactions among patients with hair loss due to alopecia areata and related conditions is effective, new findings suggest, as the test allows for robust evidence for tailored clinical management.1 The analysis which resulted in these findings—led by Chengcheng Feng, from the department of … Read more
Tofacitinib treatment of alopecia areata may be efficacious for pediatric patients due to rapid regrowth among responders, new findings suggest, though the medication’s durability necessitates additional research.1 These findings followed the conclusion of a recent study authored by Rahul Mahajan, from the department of dermatology, venereology, and leprology at the Post Graduate Institute of Medical … Read more
Archyde > Long-Term Efficacy and Safety of Ritlecitinib in Alopecia Areata Table of Contents 1. Long-Term Efficacy and Safety of Ritlecitinib in Alopecia Areata 2. Promising Results: Hair Regrowth Sustains Over Time 3. Safety Profile: Favorable Despite Side Effects 4. What Are the Key Differences Between the ALLEGRO-LT Study and Previous Ritlecitinib Trials for AA? … Read more
TOPLINE: Ritlecitinib demonstrates long-term improvements in regrowth of scalp hair, eyebrows, and eyelashes at 24 months in adults and adolescents with alopecia areata (AA) and ≥ 25% scalp hair loss. METHODOLOGY: Researchers evaluated outcomes in 449 de novo adult and adolescent patients (mean age, 32.9 years) with AA and ≥ 25% scalp hair loss, enrolled … Read more
A New Dawn for Alopecia Areata: Baricitinib Offers Hope Patients battling severe alopecia areata can now look forward with newfound hope. The FDA’s approval of baricitinib (Olumiant) in June 2022 marks a watershed moment in the treatment of this debilitating autoimmune disorder characterized by hair loss. This revolutionary drug, initially approved for rheumatoid arthritis and … Read more
Alopecia areata, an autoimmune disorder characterized by non-scarring hair loss, has long posed significant challenges for patients and clinicians alike. With a difficult-to-predict disease course and a significant impact on physical and emotional well-being, patients have faced limited treatment options that often failed to address the underlying mechanisms of the condition. Until recently, the therapeutic … Read more
Lower serum vitamin D and zinc levels may be considered risk factors for alopecia areata, new findings suggest, suggesting that their measurement can serve as an indicator for alopecia risk and disease severity.1 These findings resulted from new research conducted for the purposes of making a thorough and systematic evaluation of any connections between alopecia … Read more
Baricitinib is safe and efficacious over 52 weeks as a treatment for severe alopecia areata, according to recent real-world findings, aligning with clinical trial results.1 These conclusions regarding baricitinib’s treatment of alopecia areata resulted from an analysis written by a team of investigators led by Carlo A. Vignolia. Vignolia works at the dermatology unit at … Read more